Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis.

Author(s): Serpell MG, Notcutt W, Collin C

Pain Clinic, Division of Developmental Medicine, Department of Anaesthetics, Gartnavel General Hospital, University of Glasgow, Glasgow, UK. [email protected]

Subject: Multiple Sclerosis View the study


Sativex is an endocannabinoid system modulator principally containing Δ(9)-tetrahydrocannabinol (THC) and cannabidiol (CBD). During a 6-week randomised controlled trial, Sativex had a clinically relevant effect on spasticity associated with multiple sclerosis (MS). Patients self-titrated oromucosal Sativex to symptom relief or maximum tolerated dose (maximum of 130 mg THC and 120 mg CBD daily). The primary objective was to evaluate the safety and tolerability of long-term treatment by recording the incidence and severity of adverse events (AEs).

Source: Journal of Neurology (Price: $40)
Share Tweet

More medical studies related to Multiple Sclerosis:

View all medical studies >>

Subscribe for daily cannabis news, announcements, and business insights.